Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option

Jeffrey H. Lipton, Tim H. Brümmendorf, Carlo Gambacorti-Passerini, Valentin Garcia-Gutiérrez, Michael W. Deininger, Jorge E. Cortes

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations

Abstract

The development of BCR::ABL1-targeting tyrosine kinase inhibitors (TKIs) has improved the prognosis of patients with chronic myeloid leukemia (CML). Although there are some common class-wide side effects, differences in safety profiles between TKIs allow physicians and patients to personalize treatment plans. Treatment selection depends on several factors, such as age, disease risk, comorbidities, and concomitant medications. In second- and later-line settings, response to previous TKIs and mutation analyses should also be used to guide TKI selection. Several strategies can be used to manage adverse events (AEs) that emerge during treatment, e.g., dose reductions/interruptions, monitoring, treatment of AEs, lifestyle modifications, prophylactic therapy, and other supportive care strategies. This review summarizes the safety profiles of the currently approved TKIs and how they impact treatment selection in the first- and later-line settings of CML, particularly regarding patient comorbidities and concomitant medications. Additionally, strategies to manage AEs of special interest with TKIs are reviewed.

Original languageEnglish (US)
Article number100968
JournalBlood Reviews
Volume56
DOIs
StatePublished - Nov 2022

Keywords

  • Adverse events
  • Chronic myeloid leukemia
  • Long-term
  • Safety
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option'. Together they form a unique fingerprint.

Cite this